SavedAdd your journal

Journals / Yeni Üroloji Dergisi / 2014 / Cilt: 9 - Sayı: 1

Is there a role of phosphodiesterase type 5 enzyme ınhibitors in the treatment of benign prostatic hyperplasia and erectile dysfunction?

Benign prostat hiperplazisi ve erektil disfonksiyon tedavisinde fosfodiesteraz tip 5 enzim inhibitörlerinin rolü var mıdır?

Yılmaz ASLAN
Özer GÜZEL
Altuğ TUNCEL
Ali ATAN
Pages
81–86
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
📊
Key Findings & Data:As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH.
💡
Conclusion & Impact:In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Erectile dysfunction (ED) is defined as persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. Benign prostatic hyperplasia (BPH) is often seen at advanced age like ED, and they share a common pathophysiologic mechanism. Both are major health problems that negatively affect the patients’ quality of life. As the first-line treatment, phosphodiesterase type 5 inhibitors (PDE5i) are used for ED, and alpha-blockers for BPH. The using of PDE5i in the treatment of lower urinary tract symptoms (LUTS) due to BPH, has been gaining popularity in recent years. Having therapeutic effects for both erectile function and LUTS, PDE5i are good candidates as a monotherapy in BPH patients. In this review, the current status of PDE5i therapy for patients with LUTS due to BPH is discussed.

Özet

Erektil disfonksiyon (ED), tatmin edici cinsel performans için gerekli ereksiyonu sağ- lama ve sürdürmedeki yetersizliğin süreklilik kazanması hali olarak tanımlanır. Benign prostat hiperplazisi (BPH) ve ED sıklıkla ileri yaşta görülmekte ve ortak fizyopatolojiyi paylaşmaktadırlar. Her iki durum hastanın yaşam kalitesini olumsuz etkileyen önemli sağlık problemleridir. ED tedavisinde fosfodiesteraz tip 5 enzim inhibitörleri (PDE5i), BPH’da alfa bloker tedaviler birinci basamak tedavi olarak kullanılmaktadır. Son yıllarda BPH’ya bağlı alt üriner sistem semptomlarının (AÜSS) tedavisinde PDE5i’lerin kullanımı gündeme gelmiş- tir. PDE5i’ler hem erektil fonksiyonları hem de AÜSS iyileştirerek BPH’da monoterapi olmaya adaydır. Bu derlemede BPH’ya bağlı AÜSS olan hastalarda PDE5i’lerin kullanımındaki güncel durum tartışılmaktadır

🔖

Cite This Article

ASLAN, Y., GÜZEL, Ö., TUNCEL, A., ATAN, A. (2014). Is there a role of phosphodiesterase type 5 enzyme ınhibitors in the treatment of benign prostatic hyperplasia and erectile dysfunction?. Yeni Üroloji Dergisi, Cilt: 9 - Sayı: 1, 81–86. https://ajindex.com/articles/337395

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20 Suppl 3:11-8
  2. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005;7:3-14
  3. Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 1995;22:285-90
  4. Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2013. http://www.uroweb.org/ gls/pdf/13_Male_LUTS_LR.pdf 5- Gacci M, Eardley I, Giuliano F et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25
  5. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9:181-90
  6. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90
  7. Akkus E, Kadioglu A, Esen A et al. Turkish Erectile Dysfunction Prevalence Study Group. Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol 2002;41:298-304. a. Kaynak eklenecek 9- Balcı M, Aslan Y, Aydın AÖ et al. Türk erkeklerinde cinsel fonksiyon bozukluğu taraması: anket çalışması. Ortadoğu Tıp Dergisi 2012:4;108-113
  8. Wespes E, Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology 2013. http:// www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf 11- Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 2011;72:197-204
  9. Elterman DS, Chughtai B, Lee RK, Te AE, Kaplan SA. Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. Rev Urol 2012;14:79-86
  10. He W, Manisha S, Victoria AK, Kimberly AD. U.S. Census Bureau, Current Population Reports, P23-209, 65+ in the United States: 2005, U.S. Government Printing Offi ce,Washington, DC 2005
  11. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995;155:477-81
  12. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637- 49. 1